Botanical and Plant Derived Drugs Market - Global Industry Insights
The botanical and plant derived drugs are obtained from medicinal plants, which contain algae, microscopic fungi or any vegetable material. They are used for treatment of various health conditions such as cardiovascular diseases, respiratory disease, central nervous system disorders, and infectious diseases. The major classes of botanical and plant derived drugs are Tarpenes and Steroids, Glycosides, Morphine Alkaloids, Ergot Alkaloids, and Vinca Alkaloids. High risk of side effects caused due to consumption of synthetic drugs such as allergic reaction and gastrointestinal upsets, drugs recalls, and high cost of specialty drugs are propelling the adoption of the botanical and plant derived drugs. Furthermore, increasing prevalence of chronic disease and low cost of botanical drugs are expected to foster the growth of botanical and plant derived drugs market.
However, stringent laws and regulations for approval of botanical drugs is a key restraint for the growth of botanical and plant derived drugs market.Moreover, increasing number of mergers and acquisitions by manufacturing companies is driving growth of the botanical and plant derived drugs market.
The botanical and plant derived drugs market is estimated to be valued at US$ 30.1 Bn in 2017, and is expected to witness a robust CAGR of 6.3% during the forecast period (2017 - 2026).
Fig: Botanical and Plant Derived Drugs Market Value (US$ Bn): 2016 - 2026
Source: Coherent Market Insights 2018
Increasing demand for effective treatment of chronic disorders coupled with launch of new products are expected to foster growth of the botanical and plant derived drugs market
In several diseases, there is no cure for chronic pain. Therefore, physicians prefer pharmacologic methods to treat pain and decrease the suffering of patients. Patients suffering from intractable chronic pain, which cannot be managed with conventional treatment methods, prefer botanical and plant derived drugs. Lung cancer is the leading cause of death in the Eastern, Southern, and Southeastern Asia.
According to the 2013- International Agency for Research on Cancer data, in 2012, 1,033,881 cases of lung cancer occurred only in Asia. In addition, Eastern, Southern, and Southeastern Asia region accounts for 56% of the world’s population and contributes to 44% of the total cancer cases, worldwide according to the statistics mentioned in The Cancer Atlas. High cost of developing and manufacturing conventional drugs is propelling demand for alternative solution, such as plant-derived drugs that cost less than conventional drugs. Requirement of less technical experts and low capital investment for manufacturing botanical and plant-derived drugs. For instance, in October 2016, Napo Pharmaceuticals, Inc. launched Mytesi, an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on Antiretroviral Therapy (ART).
Furthermore, in February 2015, Nature’s Power Nutraceuticals (NP Nutra) launched seven new products, which include Aloe Vera 100:1 Freeze-dried (Organic), Yacon Leaf Powder (Organic), Nopal Powder (organic), Pea Protein Powder 80% (organic), Hemp Protein Powder 45% (organic), and NutraProtein Power Blend.
Favorable government policies and supportive initiatives by various organizations also aid in growth of the botanical and plant derived drugs market
Government is taking initiatives for the development of new plant-based drugs with herbal medicine gaining significant traction from the global healthcare systems. China utilizes herbal medicines for treatment of diseases such as acute respiratory syndrome. World Health Organization (WHO) along with economies such as India, China, the US, and Nigeria are majorly investing in research and development for herbal drugs.
Furthermore, legalization of medicinal cannabis is expected to boost growth of the botanical and plant derived drugs market. For instance, in 2016, marijuana legalization in America reached a tipping point as the medical marijuana became legal in some of the states. In February 2016, the Australian Government amended the Narcotics Drugs Act 1967 to allow cultivation of cannabis for medicinal or scientific purposes under a national licensing scheme, which is expected to favor growth of the botanical and plant derived market. The legalization of medicinal cannabis is expected to increase research on medicinal cannabis offering a valuable medical option for treatment, which in turn is supporting growth of botanical and plant derived drugs market in near future.
Key players operating in the market include Bayer Healthcare, GlaxoSmithKline, Pfizer, Inc. Sanofi, Actelion Pharmaceuticals, Aimil Pharmaceuticals, Allergan, AstraZeneca, Boehringer Ingelheim, and GW Pharmaceuticals.
Botanical and plant derived drugs contain active ingredients derived from plants. The botanical drug is a mixture of plant materials that include whole plant, part of plants, fungi or algae. Plants have been used as a source of medicine since past, owing to side effects caused due to consumption of synthetic drugs the botanical and plant derived drugs are preferred over the synthetic drugs.
Furthermore, the botanical drugs are clinically evaluated for safety and efficacy just as conventional drugs. Besides, this legalization of medical cannabis is also expected to foster growth of the botanical and plant derived drugs market.
The global botanical and plant derived drugs market is projected to witness significant growth over the forecast period, owing to legalization of medical cannabis. Medical cannabis was legalized in the Czech Republic, in 2013, Argentina and Chile in 2015, and in 2016, marijuana legalization in America reached a tipping point, as the medical marijuana became legal in some of the states.
Hence, many manufacturers are focused on research and development on medical cannabis to launch new drugs. For instance, one of the drug by GW Pharmaceuticals, Epidiolex consists of cannabidivarin (CBDV) is in developmental process, which will be used in clinical trials for treatment resistant epilepsy, supported by NSW and Queensland government in 2016.
Furthermore, increasing number of chronic disease supports the growth of botanical and plant derived drugs, as lung cancer accounts for the leading cause of death in the Eastern, Southern and Southeastern Asia. The region holds for 56% of the world’s population and contributes to 44% of the total cancer cases worldwide according to the statistics mentioned in the Cancer Atlas.
.Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 35 market data tables and 41 figures on "Global Botanical and Plant Derived Drugs Market- Global forecast to 2026”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.